NextFin News - The internal machinery of the Food and Drug Administration is currently grinding against a friction point that has little to do with clinical trials and everything to do with the politics of public health. Tracy Beth Hoeg, the recently appointed head of the FDA’s drug center, is aggressively pushing to hire Adam Urato, a maternal-fetal medicine specialist and vocal critic of antidepressant safety, to a full-time position within the agency. The move has sent ripples through the 5,000-person Center for Drug Evaluation and Research, as Urato is the primary author of a pending citizen petition demanding that the FDA slap a "black box" warning—the agency’s most severe cautionary label—on selective serotonin reuptake inhibitors (SSRIs) used during pregnancy.
The conflict is not merely professional but deeply personal. Hoeg and Urato have a documented history of collaboration, with Urato recently defending their relationship as a standard professional friendship. However, the optics within the agency are far more blurred. Last autumn, Hoeg delivered a presentation to senior FDA officials regarding the SSRI petition, framing the research as her own. Subsequent internal reviews of the presentation slides revealed they were authored by Urato. This incident, first reported by STAT News, has fueled allegations that the agency’s leadership is bypassing traditional firewalls designed to prevent individual bias from dictating regulatory policy.
At the heart of the dispute is the safety of medications like fluoxetine and sertraline, which are currently used by more than 15% of American women. Urato’s petition alleges that these drugs cause fetal brain abnormalities and increase the risk of autism and miscarriages. While these claims are not new to the medical community, they have historically been dismissed by mainstream psychiatric and obstetric bodies as being based on "flimsy data." Critics, including Jennifer Payne of the University of Virginia, argue that Urato’s analysis fails to account for the "confounding by indication"—the reality that the underlying maternal depression itself, rather than the medication, often correlates with adverse birth outcomes.
The push for a black box warning represents a radical shift in the FDA’s posture under the administration of U.S. President Trump. Hoeg, a sports medicine physician with no prior government experience, was elevated to her post in December 2025 as part of a broader overhaul led by Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary. This new leadership has consistently favored "medical contrarians" who challenge established public health consensus on everything from vaccine mandates to fluoride in water. By attempting to bring Urato into the fold, Hoeg is effectively attempting to institutionalize a viewpoint that the medical establishment considers fringe.
The stakes for the pharmaceutical industry and public health are immense. A black box warning is often a death knell for a drug’s widespread clinical use, as it triggers strict liability concerns for physicians and immediate fear for patients. If the FDA fast-tracks this warning—as Hoeg has reportedly instructed staffers to do, shortening a nine-month review window—the result could be a mass discontinuation of treatment among pregnant women. Perinatal psychiatrists warn this would lead to a surge in maternal self-harm, substance abuse, and poor neonatal care, risks that they argue far outweigh the unproven developmental threats cited by Urato.
Legal experts suggest the agency is entering a minefield. Patti Zettler, a former FDA attorney, notes that if the agency ignores its own rigorous review protocols to satisfy a leadership mandate, it opens itself to significant litigation. The Administrative Procedure Act requires agencies to provide a "rational connection between the facts found and the choice made." If the FDA’s final decision on SSRIs appears to be the result of a pre-ordained conclusion driven by a hand-picked hire, the pharmaceutical industry will likely find a very sympathetic ear in the federal courts.
The situation at the FDA reflects a broader trend in the 2026 political landscape, where the line between independent scientific review and executive-branch ideology is becoming increasingly porous. As Hoeg continues to advocate for Urato’s hiring and the acceleration of his petition, the agency’s career scientists find themselves in an unprecedented position: defending the status quo against their own directors. The outcome of this internal power struggle will determine not just the labeling of a class of drugs, but the very credibility of the FDA as a non-partisan arbiter of safety.
Explore more exclusive insights at nextfin.ai.
